Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion

Fineline Cube Jun 29, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...

Company Drug

AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants

Fineline Cube Jun 29, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share

Fineline Cube Jun 29, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Shandong Buchang Pharmaceuticals’ BC001 Gets Clinical Trial Approval for Solid Tumors

Fineline Cube Jun 29, 2023

Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa

Fineline Cube Jun 28, 2023

China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...

Policy / Regulatory

Shanghai’s SMPA Notification: Non-Winning Bids in VBP Round 8 Can Avoid “Higher Price” Label

Fineline Cube Jun 28, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification concerning the 8th round of...

Company Legal / IP Policy / Regulatory

US FDA Issues Warning Letter to Chengdu KeCheng Fine Chemicals Over Communication Failures

Fineline Cube Jun 28, 2023

The US FDA’s Center for Drug Evaluation (CDE) issued a warning letter to China-based Chengdu...

Company Drug

Grand Pharmaceutical Initiates Phase I Study for TLX250-CDx in Renal Mass Imaging

Fineline Cube Jun 28, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...

Company Drug

Teva Pharmaceutical’s Copaxone Approved by NMPA for Multiple Sclerosis Treatment in China

Fineline Cube Jun 28, 2023

The National Medical Products Administration (NMPA) website has indicated that Israel-based Teva Pharmaceutical Industries’ (NYSE:...

Company

Fosun Pharmaceutical’s Sisram Opens Wellness Center in Chicago for Beauty and Health

Fineline Cube Jun 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the establishment of...

Company Deals

Sanyou Biopharmaceuticals and Huadong Medicine Expand Partnership on Macromolecule Therapeutics

Fineline Cube Jun 28, 2023

China-based Sanyou Biopharmaceuticals Co., Ltd has announced a licensing deal with compatriot firm Huadong Medicine...

Company Drug

Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu

Fineline Cube Jun 28, 2023

South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...

Company Drug

Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone

Fineline Cube Jun 28, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...

Company Deals

Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions

Fineline Cube Jun 27, 2023

Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...

Policy / Regulatory

CDE Issues Guidelines for New Drug Benefit-Risk Assessment in Market Approval Filings

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has released a notice outlining the guidelines for “New...

Legal / IP Policy / Regulatory

CNIPA Launches Pilot for Priority Patent Review for Macau Applicants in Mainland China

Fineline Cube Jun 27, 2023

The China National Intellectual Property Administration (CNIPA) has announced the commencement of a pilot program...

Company Drug

AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes

Fineline Cube Jun 27, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval...

Company Deals

Lion TCR Secures RMB 300 Million in Series B2 Financing to Advance Clinical Studies and Facility Construction

Fineline Cube Jun 27, 2023

Singapore-based clinical-stage biotechnology company Lion TCR has announced the successful completion of its Series B2...

Company Drug

LianBio’s Mavacamten Receives Priority Review Status from China’s CDE for oHCM Treatment

Fineline Cube Jun 27, 2023

The Center for Drug Evaluation (CDE) has indicated on its website that China-based biotech firm...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study

Fineline Cube Jun 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Posts pagination

1 … 504 505 506 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.